StockData

Hims & Hers Health vs LifeMD

HIMS and LFMD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIMS and LFMD compare

Hims & Hers Health is the larger company, worth 44 times as much as LifeMD ($4.6B against $106M).

Hims & Hers Health grew revenue faster over the last twelve months (29.8% versus 23.6% for LifeMD).

LifeMD keeps more of each dollar of sales as profit, with a net margin of 0.21% compared with −6.7% at Hims & Hers Health.

LifeMD scores higher on the StockData Score (13 against 8 for Hims & Hers Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHIMSLFMD
Size and price
Market cap$4.6B$106M
Share price$19.73$2.19
Change, 1 year−49.4%−56.7%
Change, 5 years170%−51.7%
Beta (5Y)2.031.73
Employees1,046389
StockData Score
Total score813 (better)
Valuation score03 (better)
Growth score33
Performance score13 (better)
Health score44
Dividend score00
Valuation
P/S1.6×0.6× (better)
P/B13.0×–
P/FCF560×–
FCF yield0.18% (better)−10.6%
Fair value$6.77$2.91
Margin of safety−191%24.6% (better)
Growth
Revenue growth (TTM)29.8% (better)23.6%
Revenue growth, 5Y average73.6% (better)39.1%
Net income growth (TTM)−243%–
EPS growth (TTM)−254%–
Profitability
Gross margin63.8%86.5% (better)
Operating margin−8.1% (better)−11.0%
Net margin−6.7%0.21% (better)
FCF margin0.29% (better)−5.9%
Return on equity−40.8%109% (better)
Financial health
Debt / equity0.00–
Current ratio0.92 (better)0.80
Altman Z-score1.29 (better)−2.87
Piotroski F-score55
Dividends and buybacks
Payout ratio–776%
Shareholder yield0.00%0.00%
Ownership
Held by institutions67.1%44.9%
Held by insiders10.9%18.2%
Insider net buying, 12 months−$17.1M−$54.1K (better)
Short interest, % of float24.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.